Posted by Michael Wonder on 09 May 2017
Novartis receives FDA approval for first-of-its-kind Kisqali Femara co-pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
8 May 2017 - Co-Pack allows patients ability to obtain Kisqali and Femara with a single co-pay.
Novartis announced today that the US FDA has approved the Kisqali Femara co-pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women1. The Kisqali Femara Co-Pack is the first, and only currently available, combination pack with two prescription products in advanced breast cancer.
With this FDA approval, physicians in the United States now have the flexibility to prescribe Kisqali two different ways: via the new Co-Pack or as two separate prescriptions of Kisqali and any aromatase inhibitor.
